>KOSP's pipeline was ignored in today's news, seems to me.<
The write-ups I read did mention asthma and inhaled insulin.
>Any implication for the rest of the "potential takeover targets" out there, and what pipelines would you consider most worthy of some big pharma buying out these days?<
Some of the HCV players other than IDIX would make good takeout candidates, IMO.
Market Data 
Markets 
AI
